Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study.

Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Pezzella D, di Grazia A, Erro R, Pellecchia MT, Amboni M, Trojano L, Barone P.

Parkinsonism Relat Disord. 2015 Oct;21(10):1219-26. doi: 10.1016/j.parkreldis.2015.08.024.

Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease.

Deusser J, Schmidt S, Ettle B, Plötz S, Huber S, Müller CP, Masliah E, Winkler J, Kohl Z.

J Neurochem. 2015 Nov;135(3):589-97. doi: 10.1111/jnc.13253.

Action verbal fluency in Parkinson's patients.

Rodrigues IT, Ferreira JJ, Coelho M, Rosa MM, Castro-Caldas A.

Arq Neuropsiquiatr. 2015 Jun;73(6):520-5. doi: 10.1590/0004-282X20150056.

Neuroprotective potential of Beta vulgaris L. in Parkinson's disease.

Nade VS, Kawale LA, Zambre SS, Kapure AB.

Indian J Pharmacol. 2015 Jul-Aug;47(4):403-8. doi: 10.4103/0253-7613.161263.

Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.

Kardani J, Roy I.

ACS Chem Neurosci. 2015 Sep 16;6(9):1613-25. doi: 10.1021/acschemneuro.5b00158.

The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson's Disease.

Calandria JM, Sharp MW, Bazan NG.

Cell Mol Neurobiol. 2015 Nov;35(8):1127-36. doi: 10.1007/s10571-015-0206-6.

[The protection of scorpion venom derived activity peptide against the change of dynorphin in the early Parkinson's disease rats].

Wang DM, Zhao D, Yin SM, An D, Chen W, Yu DQ, Xu H, Zhao J, Zhang WQ, Tian YX.

Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2015 Mar;31(2):120-2. Chinese. No abstract available.

A commentary on fine mapping and resequencing of the PARK16 locus in Parkinson's disease.

Trinh J, Vilariño-Güell C, Ross OA.

J Hum Genet. 2015 Aug;60(8):405-6. doi: 10.1038/jhg.2015.76. No abstract available.

Filling in the missing puzzle piece between cardiac MIBG scintigraphy findings and Parkinson's disease pathology.

Watanabe H, Sobue G.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):937. doi: 10.1136/jnnp-2015-310862. No abstract available.

Barriers and Facilitators for Participation in People with Parkinson's Disease.

Nilsson MH, Iwarsson S, Thordardottir B, Haak M.

J Parkinsons Dis. 2015;5(4):983-92. doi: 10.3233/JPD-150631.

Doctor--how quickly will my Parkinson's progress?

Fox SH, Ceravolo R.

Eur J Neurol. 2015 Mar;22(3):421-2. doi: 10.1111/ene.12502. No abstract available.

Characterization and quantification of freezing of gait in Parkinson's disease: Can detection algorithms replace clinical expert opinion?

Delval A, Tard C, Rambour M, Defebvre L, Moreau C.

Neurophysiol Clin. 2015 Nov;45(4-5):305-13. doi: 10.1016/j.neucli.2015.09.009. Review.

Effects of L-arginine pre-treatment in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's diseases in Balb/c mice.

Hami J, Hosseini M, Shahi S, Lotfi N, Talebi A, Afshar M.

Iran J Neurol. 2015 Oct 7;14(4):195-203.

Toward peptide-based inhibitors as therapies for Parkinson's disease.

Mason JM, Fairlie DP.

Future Med Chem. 2015;7(16):2103-5. doi: 10.4155/fmc.15.139. No abstract available.

Opicapone for motor fluctuations in Parkinson's disease.

Devos D, Moreau C.

Lancet Neurol. 2015 Dec 22. pii: S1474-4422(15)00346-4. doi: 10.1016/S1474-4422(15)00346-4. [Epub ahead of print] No abstract available.